{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"2"}]}],"title":"Investigator-Assessed: CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"8"}]}],"title":"Investigator-Assessed: PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Independent Review: CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"4"}]}],"title":"Independent Review: PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"108"}],"units":"Participants"}],"description":"OR is defined as the number of participants with evidence of complete response (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.","groups":[{"description":"Participants with histologically confirmed cutaneous advanced or metastatic melanoma (Stage IIIC or Stage IV), with a BRAF (a human gene encoding for protein called B-Raf, which is involved in a signaling pathway and is important for cell growth) V600 E/K mutation-positive tumor sample as determined via the central BRAF mutation assay, received a Trametinib 2 milligram (mg) tablet once daily until disease progression, death, or withdrawal.","id":"OG000","title":"Trametinib"},{"description":"Participants with histologically confirmed cutaneous advanced or metastatic melanoma (Stage IIIC or Stage IV), with a BRAF V600 E/K mutation-positive tumor sample as determined via the central BRAF mutation assay, received an intravenous (IV) dose of Dacarbazine 1000 mg per square meter every 3 weeks or Paclitaxel 175 mg per square meter every 3 weeks at the discretion of the investigator, provided the participant had not received that type of chemotherapy before randomization, until disease progression, death, or withdrawal.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)","title":"Number of Participants With OR as Assessed by the Investigator and Independent Review","type":"SECONDARY","unitOfMeasure":"Participants"}